Fennec Pharmaceuticals (FENC) Income from Continuing Operations (2010 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Income from Continuing Operations came in at 4714000.0 in Q4 2025, down 276.22% YoY from 2675109.6 in Q4 2024, and down 656.66% on a QoQ basis from 623000.0 in Q3 2025.
Powered by 
Analysis
Fennec Pharmaceuticals (FENC) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 16 years of Income from Continuing Operations data on file, last reported at 4714000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 276.22% year-over-year to 4714000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 9656000.0 (down 2350.82% YoY) and the FY2025 annual result came in at 6207000.0, down 46.91% from the prior year.
- Income from Continuing Operations fell to 4714000.0 in Q4 2025, from 623000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 12906000.0 in Q1 2024 to a low of 8050000.0 in Q3 2022.
- A 5-year average of 3286200.0 and a median of 4235500.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 316.58% — and 2025, when it tumbled 276.22%.
- Tracing FENC's Income from Continuing Operations over 5 years: stood at 4256000.0 in 2021, then plunged by 58.04% to 6726000.0 in 2022, then jumped by 61.08% to 2618000.0 in 2023, then surged by 52.14% to 1253000.0 in 2024, then plunged by 276.22% to 4714000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 4714000.0 (Q4 2025), 623000.0 (Q3 2025), and 3155000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn | 1.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.97 Mn |
| Dec 31, 2025 | -2.63 Mn |
| Sep 30, 2025 | -623,000.00 |
| Jun 30, 2025 | -3.15 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -1.50 Mn |
| Sep 30, 2024 | -5.71 Mn |
| Jun 30, 2024 | -5.51 Mn |
| Mar 31, 2024 | 12.91 Mn |
| Dec 31, 2023 | -2.62 Mn |
| Sep 30, 2023 | -1.77 Mn |
| Jun 30, 2023 | -5.38 Mn |
| Mar 31, 2023 | -5.96 Mn |
| Dec 31, 2022 | -6.73 Mn |
| Sep 30, 2022 | -7.99 Mn |
| Jun 30, 2022 | -5.06 Mn |
| Mar 31, 2022 | -3.60 Mn |
| Dec 31, 2021 | -4.26 Mn |
| Sep 30, 2021 | -4.22 Mn |
| Jun 30, 2021 | -3.92 Mn |